From: A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden
Total PSA (ng/ml)
No cancer detected
Low-grade cancer
High-grade cancer
2.6 to 4.0
241 (84%)
43 (15%)
3 (1%)
4.1 to 10.0
274 (74%)
79 (21%)
18 (5%)
10.1 to 20.0
27 (50%)
18 (33%)
9 (17%)
>20.0
6 (21%)
12 (43%)
10 (36%)